Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension

Atherosclerosis

Volumn 192, Issue 1, 2007, Pages 148-154

  Preston, Richard A ^a   Coffey, James O ^a   Materson, Barry J ^a   Ledford, Marlies ^a   Alonso, Alberto B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelium derived factors; Fibrinolysis; Hypertension; Plasminogen activators; Platelet activation; Platelet P selectin

Indexed keywords

PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD VESSEL INJURY; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION;

BLOOD PRESSURE; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ACTIVATION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34247138810     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.028     Document Type: Article

References (33)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115-129 mmHg. JAMA 202 (1967) 116-122
3. Preston R.A., Baltodano N.M., Cienki J., and Materson B.J. Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. J Hum Hypertens 13 (1999) 249-255
4. Preston R.A., Ledford M.R., Materson B.J., et al. Effects of severe, uncontrolled hypertension on endothelial activation: sVCAM-1, sICAM-1, and vWF. J Hypertens 20 (2002) 871-877
5. Blann A.D., Nadar S., and Lip G.Y. Pharmacological modulation of platelet function in hypertension. Hypertension 42 (2003) 1-7
6. Lip G.Y., and Blann A.D. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 101 (2000) 218-220
7. Wagner D.D. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 25 (2005) 1321-1324
8. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers and inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
9. Koyama H., Takaaki M., Fukomoto S., et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 108 (2003) 524-529
10. Stumpf C., John S., Jukic J., et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens (2005) 995-1000
11. Minuz P., Patrignani P., Gaino S., et al. Determinants of platelet activation in human essential hypertension. Hypertension 43 (2004) 64-70
12. Camilletti A., Moretti N., Giacchetti G., et al. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am J Hypertens 14 4 Pt 1 (2001) 382-386
13. De Taeye B., Smith L.H., and Vaughan D.E. Plasminogen activator-1: a common denominator in obesity, diabetes, and cardiovascular disease. Curr Opin Pharmacol 5 (2005) 149-154
14. Poli K.A., Tofler G.H., Larson M.G., et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 101 (2000) 264-269
15. Eliasson M., Jansson J.H., Nilsson P., and Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J Hypertens 15 (1997) 349-356
16. Held C., Hjemdahl P., Rehnqvist N., et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Circulation 95 (1997) 2380-2386
17. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
18. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., and Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342 (1993) 1076-1079
19. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., and Hennekens C.H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341 (1993) 1165-1168
20. Brown N.J., Nakamura S., Ma L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58 (2000) 1219-1227
21. Kaikita K., Fogo A.B., Ma L., et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104 (2001) 839-851
22. Srikumar N., Brown N., Hopkins P., et al. PAI-1 in human hypertension: relation to hypertensive groups. Am J Hypertens 15 (2002) 683-690
23. Lemne C., and De Faire U. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 26 (1996) 692-697
24. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diab/Metab Res Rev 16 (2000) 192-201
25. Nordt T.K., Schneider D.J., and Sobel B.E. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 89 (1994) 321-330
26. Kruszynska Y.T., Yu J.G., Olefsky J.M., and Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49 (2000) 633-639
27. Vague P., Juhan-Vague I., Chabert V., Alessi M.C., and Atlan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38 (1989) 913-915
28. McGill J.B., Scneider D.J., Arfken C.L., Lucore C.L., and Sobel E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 42 (1994) 104-109
29. Jain S.K., Nagi D.K., Slavin B.M., Lumb P.J., and Yudkin J.S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 10 (1993) 27-32
30. Fogari R., Zoppi A., Preti P., et al. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 14 (2001) 921-926
31. Jeng J.R., Sheu W.H., Jeng C.Y., Huang S.H., and Shieh S.M. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 9 (1996) 484-490
32. Koh K.K., Cardillo C., Bui M.N., et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 99 (1999) 354-360
33. Newby D.E., Wright R.A., Labinjoh C., et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99 (1999) 1411-1415